Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KRAS | P01116 | 4/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | POLD1 | P28340 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | POLG | P54098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327007 | 1.00 | FUT5 (0.38) | FUT5POLBKRASPOLA1POLD1 | |
| SCHEMBL24971484 | 0.93 | FUT5 (0.39) | FUT5POLBKRASPOLA1POLD1 | |
| SCHEMBL22327091 | 0.90 | FUT5 (0.41) | FUT5POLBKRASPOLA1POLD1 | |
| SCHEMBL22327062 | 0.87 | POLG (0.44) | POLBPOLA1POLD1P2RY2P2RY4 | |
| SCHEMBL22327104 | 0.87 | POLB (0.47) | POLBPOLA1POLD1 | |
| SCHEMBL22327013 | 0.87 | ENTPD1 (0.38) | POLB | |
| SCHEMBL22327254 | 0.83 | FUT5 (0.38) | FUT5POLBKRASPOLA1POLD1 | |
| SCHEMBL22327234 | 0.83 | FUT5 (0.38) | FUT5POLBKRASPOLA1POLD1 | |
| SCHEMBL17225222 | 0.82 | POLB (0.44) | FUT5POLBKRASPOLA1POLD1 | |
| SCHEMBL26068621 | 0.81 | POLG (0.42) | POLBPOLA1POLD1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | FUT5 1476/4885POLB 2/4885KRAS 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.